Johnson Stelara (ustekinumab) reaches major endpoint in Phase 3 clinical trial for severe ulcerative colitis in treatment

today, Janssen, a subsidiary of Johnson and Johnson'scompany,(http://, announced that its development of Steeinumab had reached its main end in a phase 3 clinicaltrial(http://of severe ulcerative colitis in the treatment of severe ulcerative colitis, uc, as a maintenance therapy significantly improved the proportion of patients who reached clinical remissionthese positive clinical outcomes promise to further expand Stelara's indications and provide a new treatment option for UC patientsAbout ustekinumab
ustekinumab is a human IL-12 and IL-23 antagonistIL-12 and IL-23 are important cytokines in the body that regulate the immune system and immune-mediated inflammatory diseasesUstekinumab has been approved by theFDA(http://for the treatment of psoriasis and Crohn's diseaseIf approved by the FDA, it would represent a treatment option that uses a new mechanism to treat UCIn the phase 3 trial, called UNIFI, 44 percent of adult patients with moderate- and severe UC who received subcutaneous injections every 8 weeks after one year of treatment achieved clinical remission, and 3 out of every 12 weeks who received ustekinumab treatment8% reached clinical remission, compared with 24% of patients receiving placebo treatment (p.001)Janson filed a supplemental biologics license (s) application with the FDA for USE in the treatment of UC for ustekinumab in DecemberThese positive Phase 3 data suggest that UC patients are expected to welcome a treatment option with a new mechanism this year